Universal Registration Document

Overview

The report describes Abivax's progression into global Phase 3 trials of obefazimod for ulcerative colitis, with enrollment beginning in October 2022. It reports that the company generated no revenue because its projects remained at an early development stage. The report also covers the acquisition and subsequent merger of Prosynergia and identifies a workforce of 24 full-time employees as of March 31, 2023.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: Ends 31 December 2022
Publication date: 4 May 2023
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services